Second, changes in hepatic insulin clearance or transient compensatory hyperinsulinemia related to concurrent background therapies (e.g. use of insulin secretagogues or withdrawal/alteration of other agents) might increase measured fasting insulin independently of insulin sensitivity (32). This evidence concerns the gene INS and Hyperinsulinemia.